

Leveraging patient-reported outcome measures for optimal dose selection in early phase cancer trials

Bill Byrom, Anthony Everhart, Paul Cordero, Chris Garratt, Tim Meyer

Submitted to: JMIR Cancer
on: July 24, 2024

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript.....	4
---------------------------------	----------

Preprint
JMIR Publications

Leveraging patient-reported outcome measures for optimal dose selection in early phase cancer trials

Bill Byrom¹ PhD; Anthony Everhart² MD, FACP; Paul Cordero³ PhD; Chris Garratt⁴ MBChB, FFPM; Tim Meyer⁵ MBBS, PhD

¹Signant Health Sandwich GB

²Signant Health Blue Bell US

³Sanofi Pharmaceuticals London GB

⁴Orion Pharma Nottingham GB

⁵University College London London GB

Corresponding Author:

Bill Byrom PhD

Signant Health

Unit 2 (B819)

Hugin Lane Discovery Park

Sandwich

GB

Abstract

While patient-reported outcome measures (PROMs) are regularly incorporated into phase III clinical trials, there has been little use of PROMs in early phase trials [1]. However, the patient perspective is a vital element of fully understanding dose-toxicity and selecting an optimal dose. This viewpoint paper reviews the rationale for, and practical approach to, collection of patient-reported outcomes (PRO) data in early-phase oncology drug development, and the rationale for electronic collection.

(JMIR Preprints 24/07/2024:64611)

DOI: <https://doi.org/10.2196/preprints.64611>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in http://www.jmir.org/preprint/64611

Original Manuscript

Leveraging patient-reported outcome measures for optimal dose selection in early phase cancer trials

Bill Byrom¹, Anthony Everhart², Paul Cordero³, Chris Garratt⁴, and Tim Meyer⁵

1: Signant Health, Nottingham, UK; 2: Signant Health, Blue Bell, PA, USA; 3: Sanofi Pharmaceuticals, London, UK; 4: Orion Pharma, Nottingham, UK; 5: University College London, London, UK.

Corresponding author: Bill Byrom, bill.byrom@signanthealth.com, ORCID: 0000-0002-9186-4271

Abstract


While patient-reported outcome measures (PROMs) are regularly incorporated into phase III clinical trials, there has been little use of PROMs in early phase trials [1]. However, the patient perspective is a vital element of fully understanding dose-toxicity and selecting an optimal dose. This viewpoint paper reviews the rationale for, and practical approach to, collection of patient-reported outcomes (PRO) data in early-phase oncology drug development, and the rationale for electronic collection.

Keywords

Clinical trials; early phase; dose finding; patient-reported outcomes; PROs; electronic patient-reported outcomes; ePRO; PRO-CTCAE; adverse events; tolerability.

Dose Finding in Oncology Drug Development


Traditional dose finding in oncology clinical drug development has focused on determining the maximum tolerated dose, with the assumption that the efficacy-dose relationship follows a steep monotonic increasing curve. By this assumption, the recommended dose is defined as the highest dose in which dose-limiting toxicity is not observed. Typical early phase programs (Figure 1) often employ a 3+3 dose escalation design in which subsequent cohorts of 3 patients are studied, each receiving a higher dose than the last. Dose levels often follow a modified Fibonacci sequence whereby dose increments become smaller as the dose increases [2]. When dose limiting toxicity (DLT) is observed in at least one patient, the dose level is repeated in a further cohort of 3 patients, and if DLT observed again, further escalation stops, identifying the previous dose as the recommended maximum tolerated dose (MTD) to take forward. Further study of the recommended dose is achieved, often using a seamless phase I-II design, by recruiting an additional, larger group of patients into a dose expansion study. The primary endpoint in an expansion cohort is usually to determine efficacy, most frequently according to radiological response rate. Additionally, further safety data is gathered and pharmacodynamic markers may also be developed.

Figure 1. Traditional early phase oncology dose finding studies

This approach has been acceptable for cytotoxic chemotherapy drugs due to their steep dose-response relationships, their limited drug target specificity, and the willingness of patients to trade off substantial toxicity to treat serious, life-threatening diseases [3]. However, it may lead to the recommendation of higher doses and a sub-optimal tolerability profile when used in dose finding for modern, more targeted oncology drugs, such as kinase inhibitors and monoclonal antibodies (Figure 2). In these cases, the wider therapeutic index means that a range of doses may show relevant efficacy, and doses below the MTD may have similar efficacy with reduced toxicity [4]. This can be particularly important because targeted therapies are often taken for much longer periods of time during which lower grade, persistent symptomatic toxicities can present a greater challenge to patients [3]. Dose finding limitations have been illustrated in 26% of FDA-approved kinase inhibitors (2001–2015) requiring post-marketing requirements/commitments to study alternative doses [5].

Better characterizing dose-response to optimize dose finding has been underlined by the FDA's Project Optimus, which aims to reform how doses are selected in oncology clinical trials, with particular focus on maximizing efficacy and optimizing safety and tolerability [6]. This led to their subsequent draft guidance on dose optimization for new cancer treatments [3]. Studying more dose levels in the dose expansion study may be one approach to enable this, and may better enable characterization of the dose-response relationship, albeit qualitatively given the likely small cohort sizes.

Figure 2. Dose-response relationships and optimal dose selection for cytotoxic chemotherapy drugs and targeted therapies



Understanding Tolerability


Tolerability is defined in good clinical practice as “the degree to which overt adverse effects can be tolerated by the subject” [7]. In oncology, assessment of tolerability typically comprises clinician-reported treatment-related adverse events (AEs), for example using the Common Terminology Criteria for Adverse Events (CTCAE) [8], along with other data such as dose modifications, discontinuations and interruptions, safety biomarkers, hospitalization, and death [9]. However, these tools and data fail to fully account for the patient perspective or to fully measure the impact of AEs on the patient’s activities and quality of life. In fact, many studies comparing physician and patient reports of treatment-related AEs have consistently shown underreporting and reduced severity rating in physician interpretations compared to patient reports [10-17]. This represents a challenge for drug developers in accurately quantifying the dose-toxicity relationship and limits the ability to define optimal dose, leading to greater risk of exposing greater numbers of patients to doses that are too high, potentially resulting in increased discontinuation and a less favorable safety profile.

For example, measuring the frequency of individual AEs reported by patients using the full patient-reported outcomes version of the CTCAE, the PRO-CTCAE item bank [18], Veitch and colleagues evaluated the associated frequency of reporting of the same AEs by physicians using the CTCAE [10]. They found that all 50 AEs reported by at least 10% of patients undergoing cancer treatment (n=243) were consistently under-reported by physicians using the CTCAE, in some cases markedly.

For example, 9 AEs were identified at least 50-times less frequently by physicians : decreased libido (31.4% vs. 0.1%), palpitations (14.7% vs. 0.1%), wheezing (14.5% vs. 0.2%), voice alteration (14.1% vs. 0.2%), hiccups (13.9% vs. 0.1%), hyperhidrosis (23.9% vs. 0.4%), vaginal dryness (11.0% vs. 0.1%), nail ridging (10.0% vs. 0.2%), and urinary incontinence (10.0% vs. 0.2%). Further, 19 CTCAE items were reported 1% or less of the time by physicians, compared to 10.0% to 31.4% by patients.

A further study in 1,933 patients with a variety of oncology conditions reported under-estimation of AE severity by clinicians in comparison to patient reports [11]. The frequency of symptoms assessed as moderate or severe by patients and physicians, respectively, were: pain (67 vs. 47%), fatigue (71 vs. 54%), generalized weakness (65 vs. 47%), anorexia (47 vs. 25%), depression (31 vs. 17%), constipation (45 vs. 30%), poor sleep (32 vs. 21%), dyspnea (30 vs. 16%), nausea (27 vs. 14%), vomiting (14 vs. 6%) and diarrhea (14 vs. 6%) (Figure 3).

Figure 3. Physician under-estimation of treatment-related adverse event severity in patients undergoing cancer treatment (n=1,933), after Laugsand et al. [11]



These examples demonstrate that physician assessment of patient AEs may be both incomplete and under-estimated in comparison to the patient perspective. Reasons for this may include patient difficulties in spontaneously raising or describing AEs, patient fears of delay or discontinuation of

treatment options in which they have high expectations of positive results, introduction of clinician subjectivity, and time constraints and practical limitations with current physician tools.

While valuable in addressing the under-reporting and lower scoring of AE severity by physicians, the PRO-CTCAE alone fails to assess the cumulative impact of the AE profile and the effects on functioning and quality of life. Cumulative impact may be especially important in newer treatments taken for sustained periods of time, where multiple, concurrent low-grade but persistent AEs may together represent an intolerable burden for the patient. As we describe later, supplementing the rating of individual AEs with an overall single item measure of the cumulative impact of AEs (e.g., using the Functional Assessment of Cancer Therapy – Item GP5 (FACT GP5) [19], or item 168 from the EORTC item library [20]), and the adverse impact on patient physical function and role function (e.g., measured using the associated EORTC Quality of Life Questionnaire – Core Questionnaire (EORTC QLQ-C30) [21]) provides valuable assessment of the impact of the AE profile experienced.

Using Patient-Reported Outcomes in Early Phase Oncology Trials

While the use of PROMs is increasingly incorporated into phase III clinical trials, and regulatory recommendations on measurement strategy have been recently published by FDA [22], there is little use of PROMs in early phase trials [1]. Barriers to adoption in early phase oncology studies include a lack of guidance regarding PROM selection, concerns relating to dealing with missing PRO data, overburdening site staff and patients, handling patient and data queries [23], and low power associated with small sample sizes. Nonetheless, the patient perspective is a vital element of fully understanding dose-toxicity and selecting optimal dose for later phase development.

Adverse Events

While in later phase trials there is typically enough understanding of the AE profile of the investigational treatment to enable reliable pre-selection of items for measurement (e.g., using a small subset of PRO-CTCAE items) the same is not true for first in human and other early phase trials. Pre-clinical data may provide some signals to drive thinking, but these are unlikely to be robust and comprehensive, and while the AE evidence from other drugs with the same mechanism of action may be available and relevant, this is not always the case. The full PRO-CTCAE instrument contains 124 items across 78 distinct terms [18], and this is impractical to use in a full list format for regular ongoing measurement.

Van Rensburg and colleagues [24] used a statistical approach to develop a reduced list of PRO-CTCAE items considered most likely to occur in a phase I population using the same dataset reported by Veitch [10]. Using that dataset, they eliminated AEs recorded less than 5% of the time;

those recorded as “mild” severity by at least 75% of patients; and AEs associated with interference scores of “not at all”, frequency scores or “never”, or amount scores of “not at all” by at least 80% of patients. Finally, terms with the lowest internal reliability within each organ system domain as measured using Cronbach’s alpha, were also eliminated. With further refinements from physician perspectives, this led to a tailored PRO-CTCAE survey consisting of 58 items assessing 30 terms. While a useful and interesting approach, the generalizability of this reduced survey may be limited by the relatively small sample size, the limited set of treatments and tumor types represented, and the risk that using historical data may miss important aspects of tolerability for new, targeted therapies. When selecting a reduced set of pre-defined items, it is helpful, as PRO-CTCAE recommends and allows, to include a free text item to capture other important AEs not listed [25], and to use this information to allow the item list to adapt with the emerging understanding gained through continued study.

Because the PRO-CTCAE items are grouped by organ system domains, it is possible to optimize completion of the full item list compared to an individual symptom-by-symptom approach (Figure 4a). Alternatively, a free-text approach asking patients to list and rate the AEs that contribute most to their overall impact rating (scored using the FACT GP5 item, for example) might provide a less burdensome approach (Figure 4b). Leveraging an electronic PRO (ePRO) solution, using a smartphone app for example, would enable free-text symptom text to be resurfaced as a list of existing AEs to be easily re-scored at future time-points.

Figure 4. Approaches to simplify adverse event capture and scoring

(a)

In the last 7 days, have you had any symptoms that affect your mouth, swallowing or speaking?

- ☒ Dry Mouth
- ☐ Difficulty swallowing
- ☐ Mouth / throat sores
- ☐ Cracking at the corners of the mouth
- ☐ Voice quality changes
- ☐ Hoarseness

In the last 7 days, what was the SEVERITY of your DRY MOUTH at its WORST?

- ☐ None
- ☐ Mild
- ☐ Moderate
- ☐ Severe
- ☐ Very severe

(b)

Overall impact of side effects

I am bothered by side effects of treatment

- ☐ Not at all
- ☐ A little bit
- ☒ Somewhat
- ☐ Quite a bit
- ☐ Very much

Contributing events

Please record which side effects have been important in bothering you in the past 7 days

1. Please describe your symptom in as few words as possible. Record multiple symptoms separately.

constipation

2. In the last 7 days, what was the SEVERITY of THIS SYMPTOM at its WORST?

- ☐ None
- ☐ Mild
- ☐ Moderate
- ☐ Severe
- ☐ Very severe

Add symptom

(a) Using organ system grouping, (b) collecting most bothersome adverse events associated with overall impact score.

Collecting the most bothersome AEs (Figure 4b) has similarities to some existing PROMs that measure “most bothersome symptoms” (MBS). For example, MBS has been shown to be a useful, patient-centric measure of migraine symptoms [26, 27], and is referred to in the patient-focused drug development guidance published by FDA [28]. Challenges with collecting an MBS include how to pool data in the statistical analysis, and different symptoms becoming the most bothersome over time. However, these challenges may be less relevant when collecting the set of most bothersome AEs to understand the dose toxicity relationship in early phase cancer trials.

Other recommended PROMs

The Friends of Cancer whitepaper [9] and FDA draft guidance on PROs in cancer trials [22] both recommend that in addition to the collection and scoring of individual AEs, an overall measure of the AE impact is included, along with measures to assess the impact of treatment on physical function and role function, although the FDA guidance is more focused towards use in confirmatory trials. A single item to score the overall impact of AEs, such as the FACT GP5 [19], or Q168 of the EORTC Item bank [20], is important as it enables the patient to account for the impact of any AEs not covered by PRO-CTCAE administration, and to attach greater importance to the combined impact of multiple low-level AEs. This understanding may be particularly important in assessing the impact of newer treatments taken over longer periods of time. The FDA have identified measures of physical function and role function they consider suitable, including the EORTC QLQ C30 physical function and role function subscales [21] and the Patient-Reported Outcomes Measurement Information System (PROMIS) physical function scale [29].

Mitigating barriers to PROM adoption in early phase

As described earlier, barriers to the adoption of PROMs in early phase cancer trials include: a lack of

guidance regarding PROM selection, concerns relating to dealing with missing PRO data, overburdening site staff and patients, handling patient and data queries [23], and low power associated with small cohorts. We address PROM selection in the discussion above. Dealing with missing data is always an important consideration in clinical research, as different missing data approaches rely upon assumptions that, if violated, can lead to biased estimates. Although in early phase researchers may use less formal approaches to interpreting the data and determining optimal dose, it will remain important to consider the impact of missing data using a variety of sensitivity evaluations.

In terms of patient burden, the UK National Cancer Research Institute Consumer Forum survey indicated that most patients and carers affected by cancer and involved in research activities (n=57) were willing to spend up to 15 minutes per day completing PROMs [23]. This time duration seems high for frequent collection, but perhaps reflects the value that patients see in communicating this data to their treating physician. The measures we have discussed above typically employ a 7-day recall period and it is therefore most likely that a weekly completion schedule would be recommended. Median per-item completion rates of PROMs commonly used in oncology trials have been reported as 6 – 14 s [30], which suggests that a weekly PROM assessment of (for example) the PRO-CTCAE implemented using the approach outlined in Figure 4a, an overall AE impact item, the physical function and role function subscales of the QLQ-C30 (5 and 2 items respectively) might translate to an average completion time of less than 5 minutes per week. This seems to be a feasible assessment strategy, and ensuring a flexible completion window across more than one day may drive higher completion rates.

The remaining barriers cited may be mitigated by electronic collection of PRO data, for example using an electronic patient-reported outcomes (ePRO) smartphone app. The burden on site staff and patients during busy clinic visits can be mitigated by enabling at-home completion, and electronic tools can eliminate data queries by prohibiting ambiguous or invalid entries. The easy implementation of longer lists of items using branching logic to speed completion is only practical using an electronic approach. Further, use of ePRO solutions can also lead to reduced missing data through alarms and reminders and remote monitoring to drive on-time completion.

Electronic collection of PRO data may be perceived as a significant additional cost relative to the smaller numbers of patients involved in early phase studies, but this should be considered in the context of the value of the data. The more frequent assessment schedules and the nature of the measures implemented drives the use of electronic solutions. In the context of the increased expense of studying more patients in early phase due to the need to better characterize dose-response, the use

of ePRO to drive more accurate, reliable data may lead to accurate decision making using relatively smaller sample sizes and offset the cost of ePRO many times over.

Smaller sample sizes associated with early phase studies may limit the robust characterization of the dose-response relationship, but this limitation is not unique to PRO data and also applies to other measures of efficacy and tolerability that inform dose selection. A thoughtful approach is required to balance the cost of increased sample size with the statistical robustness of dose-response characterization.

Conclusion

There is growing interest in more completely quantifying the dose-response relationship to inform optimal dose determination for new oncological treatments. PROs play a vital role in understanding dose-tolerability profiles, especially as treatment-related AEs tend to be under-reported and under-scored by physicians. While AE profiles are less well understood in early phase drug development, this should not prevent the capturing of this data to inform dose selection decisions as early as the first-in-human study using some of the approaches discussed in this paper.

Of course, we lack experience in interpreting PRO tolerability data from such early studies and need to remember that we may well not have adequately defined the patient population at this early stage, and so the clinical interpretation of dose-response relationships associated with the PRO and other efficacy and tolerability data needs to be interpreted with this in mind.

With newer targeted therapeutics, there is a need to learn much more about safety and tolerability across a wide range of doses, and the current dose finding models focusing on a single “optimal” dose may no longer work. A fundamental element of the decision-making process for determining safety and tolerability currently missing is the patient experience. It has been assumed that the physician, through patient interaction and AE reporting, can provide a sufficient reflection of the patient experience, but the evidence demonstrates that this is not reliable. Some important symptoms for patients are missed completely. The severity of other symptoms is underreported. Further, with newer targeted agents, AEs may accumulate over time and the chronic nature or combination of events may make a dose become intolerable for the patient later. If the patient perspective is not considered, there is a risk of selecting dose groups that are too high, leading to reduced compliance. It is therefore necessary to build a PROM assessment strategy for early phase trials that combines elements of well-established scales to assess safety and tolerability in a package that is practical and not burdensome, yielding vital data to support decision-making as the trial progresses. Maximizing the value of the early patient experience is ethically appropriate, feasible, and drives efficiency in

development programs and patient exposure.

Abbreviations

AE: Adverse event

CTCAE: Common Terminology Criteria for Adverse Events

DLT: Dose-limiting toxicity

EORTC: European Organisation for Research and Treatment of Cancer

FACT: Functional Assessment of Cancer Therapy

FDA: Food and Drug Administration

MBS: Most bothersome symptom

MTD: Maximum tolerated dose

PRO-CTCAE: Patient-reported outcomes version of the CTCAE

PROM: Patient-reported outcome measure

PROMIS: Patient-Reported Outcomes Measurement Information System

QLQ-C30: Quality of Life Questionnaire – Core Questionnaire

Author's Contributions

BB and AE wrote and edited the manuscript. PC, CG and TM edited the manuscript.

Conflicts of Interest

Dr Byrom and Dr Everhart are employees and Signant Health and may own stock and/or stock options. Dr Cordero is an employee of Sanofi and may own stock and/or stock options. Dr Garratt is an employee and shareholder of Orion Corporation. Professor Meyer reports consultancy: Roche, Astra Zeneca, Signant Health, GreyWolf, Guerbet, Geneos, Eisai, Beigene, and MSD; and research funding: MSD, Bayer, and Boston Scientific.

References

1. Coleman, R.L., Beck, J.T., Baranda, J.C., Jacobs, I., Smoyer, K.E., Lee, L.J., et al. The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials. *Oncology*. 2021; 99: 444-453.
2. Le Tourneau, C., Lee, J.J., Siu, L.L. Dose escalation methods in phase I cancer trials. *J Natl Cancer Inst*. 2009; 101: 708-720.

3. Food and Drug Administration. Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases, draft guidance for industry. 2023. URL: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases> [accessed 2024-06-17].
4. Murphy, R., Halford, S., Symeonides, S.N. Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective. *Front Oncol.* 2023; 13: 1144056.
5. Jänne, P.A., Kim, G., Shaw, A.T., Sridhara, R., Pazdur, R., McKee, A.E. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle. *Clin Cancer Res.* 2016; 22: 2613–2617.
6. Food and Drug Administration, Oncology Centre of Excellence. Project Optimus: Reforming the dose optimization and dose selection paradigm in oncology. 2024. URL: <https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus> [accessed 2024-06-17].
7. European Medicines Agency. ICH E9 Statistical principles for clinical trials - Scientific guideline. 1998. URL: [ICH E9 statistical principles for clinical trials - Scientific guideline | European Medicines Agency \(europa.eu\)](https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials-scientific-guideline) [accessed 2024-06-17].
8. U.S. National Institutes of Health (NIH), National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009. URL: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf [accessed 2024-06-17].
9. Basch, E., Campbell, A., Hudgens, S., Jones, L., King-Kallimanis, B., Kluetz, P. et al. Broadening the definition of tolerability in cancer clinical trials to better measure the patient experience. Friends of Cancer Research White Paper. 2018. URL: https://friendsofcancerresearch.org/wp-content/uploads/Comparative-Tolerability-Whitepaper_FINAL.pdf [accessed 2024-06-17].
10. Veitch, Z.W., Shepshelovich, D., Gallagher, C., Wang, L., Abdul Razak, A.R., Spreafico, A. et al. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. *J Natl Cancer Inst.* 2021; 113: 980-988.
11. Laugsand, E.A., Sprangers, M.A., Bjordal, K., Skorpen, F., Kaasa, S., Klepstad, P. Health care providers underestimate symptom intensities of cancer patients: A multicenter European study. *Health and Quality of Life Outcomes.* 2010; 8: 104-117.
12. Atkinson, T.M., Ryan, S.J., Bennett, A.V., Stover, A.M., Saracino, R.M., Rogak, L.J. et al. The

association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. *Support Care Cancer*. 2016; 24: 3669-3676.

13. Pavlović Mavić, M., Šeparović, R., Tečić Vuger, A., Vazdar, L. Difference in Estimation of Side Effects of Chemotherapy between Physicians and Patients with Early-Stage Breast Cancer: The Use of Patient Reported Outcomes (PROs) in the Evaluation of Toxicity in Everyday Clinical Practice. *Cancers*. 2021; 13: 5922-5929.

14. Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M. et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. *J Natl Cancer Inst*. 2009; 101: 1624-1632.

15. Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M.G. et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. *Lancet Oncol*. 2006; 7: 903-909.

16. Pakhomov, S.V., Jacobsen, S.J., Chute, C.G., Roger, V.L. Agreement between patient-reported symptoms and their documentation in the medical record. *Am J Manag Care*. 2008; 14: 530-539.

17. Dueck, A.C., Mendoza, T.R., Mitchell, S.A., Reeve, B.B., Castro, K.M., Rogak, L.J. et al. Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *JAMA Oncol*. 2015; 1: 1051-1059.

18. Basch, E., Reeve, B.B., Mitchell, S.A., Clauser, S.B., Minasian, L.M., Dueck, A.C. et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *J Natl Cancer Inst*. 2014; 106: dju244.

19. Functional Assessment of Chronic Illness Therapy (FACIT) Group. FACIT Item GP5. 2024. URL: <https://www.facit.org/measures/facit-item-gp5> [accessed 2024-06-17].

20. European Organisation for Research and Treatment of Cancer (EORTC). Item Library. 2024. URL: <https://qol.eortc.org/item-library/> [accessed 2024-06-17].

21. European Organisation for Research and Treatment of Cancer (EORTC). EORTC QLQ-C30 Scoring Manual, Third Edition. 2001. URL: <https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf> [accessed 2024-06-17].

22. Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials: draft guidance for industry. 2021. URL: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/core-patient-reported-outcomes-cancer-clinical-trials> [accessed 2024-06-17].

23. Lai-Kwon, J., Vanderbeek, A.M., Minchom, A., Lee Aiyegbusi, O., Ogunleye, D., Stephens, R. et al. Using patient-reported outcomes in dose-finding oncology trials: surveys of key stakeholders and the National Cancer Research Institute Consumer Forum. *The Oncologist*. 2022; 27: 768–777.

24. Janse van Rensburg, H.J., Liu, Z., Watson, G.A., Veitch, Z.W., Shepshelovich, D., Spreafico, A. et al. A tailored phase I-specific patient-reported outcome survey to capture the patient experience of symptomatic adverse events. *British Journal of Cancer*. 2023; 129: 612–619.
25. Bhatnagar, V., Dutcus, C., Ghiorghiu, S., Kluetz, P., Jones, L., McJunkins, K.R. et al. Supporting a patient-centric approach to dose optimization in Oncology: The essential role of patient-reported outcomes (PROs). *Friends of Cancer Research White Paper*. 2022. URL: https://friendsofcancerresearch.org/wp-content/uploads/Supporting_Patient-Centric_Approach_Dose_Optimization_Oncology-PROs.pdf [accessed 2024-06-17].
26. Lipton, R.B., Goadsby, P.J., Dodick, D.W., McGinley, J.S., Houts, C.R., Wirth, R.J. et al. Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention. *Headache*. 2022; 62: 690-699.
27. Dodick, D.W., Tepper, S.J., Friedman, D.I., Gelfand, A.A., Kellerman, D.J., Schmidt, P.C. Use of most bothersome symptom as a coprimary endpoint in migraine clinical trials: A post-hoc analysis of the pivotal ZOTRIP randomized, controlled trial. *Headache*. 2018; 58: 986-992.
28. Food and Drug Administration. Patient-focused drug development: Incorporating clinical outcome assessments into endpoints for regulatory decision-making – Draft guidance for industry. 2023. URL: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory> [accessed 2024-06-17].
29. Rose, M., Bjorner, J.B., Becker, J., Fries, J.F., Ware, J.E. Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS). *J Clin Epidemiol*. 2008; 61: 17-33.
30. Kalpadakis-Smith, A., Kusanto, B.T., Byrom, B., Everhart, A. PCR75 Assessment of completion time to optimize the administration of common patient-reported outcome measures (PROMS) in oncology clinical trials. *Value in Health*. 2023; 26: S325.